tert-butyl (S)-(1-cyclopropyl-2-(methylamino)-2-oxoethyl)carbamate | 1251951-45-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (S)-(1-cyclopropyl-2-(methylamino)-2-oxoethyl)carbamate
• 英文别名: tert-butyl N-[(1S)-1-cyclopropyl-2-(methylamino)-2-oxoethyl]carbamate
• CAS: 1251951-45-7
• 化学式: C₁₁H₂₀N₂O₃
• 分子量: 228.291
• InChiKey: SZPDAMUTNFTJSO-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.04
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  67.43
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-(1-cyclopropyl-2-(methylamino)-2-oxoethyl)carbamate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 (S)-N-(1-cyclopropyl-2-(methylamino)-2-oxoethyl)-5-(3-fluoro-4-(((4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)thio)methyl)phenyl)furan-2-carboxamide
  参考文献：
  名称：

  Development of matrix metalloproteinase-13 inhibitors – A structure-activity/structure-property relationship study

  摘要：

  A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhibitor 2, compound 31 was identified which exhibited microsomal hal-flife higher than 20 min, kinetic solubility higher than 20 mu M, and a permeability coefficient greater than 20x10(-6) cm/s. Compound 31 also showed excellent in vivo PK properties after IV dosing (C-max = 56.8 mu M, T-1/2 (plasma)= 3.0 h, Cl = 0.23 mL/min/kg) and thus is a suitable candidate for in vivo efficacy studies in an OA animal model.

  DOI：

  10.1016/j.bmc.2018.08.020
• 作为产物：
  描述：

  Boc-L-环丙基甘氨酸 、 甲胺 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.0h， 以74%的产率得到tert-butyl (S)-(1-cyclopropyl-2-(methylamino)-2-oxoethyl)carbamate
  参考文献：
  名称：

  Development of matrix metalloproteinase-13 inhibitors – A structure-activity/structure-property relationship study

  摘要：

  A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhibitor 2, compound 31 was identified which exhibited microsomal hal-flife higher than 20 min, kinetic solubility higher than 20 mu M, and a permeability coefficient greater than 20x10(-6) cm/s. Compound 31 also showed excellent in vivo PK properties after IV dosing (C-max = 56.8 mu M, T-1/2 (plasma)= 3.0 h, Cl = 0.23 mL/min/kg) and thus is a suitable candidate for in vivo efficacy studies in an OA animal model.

  DOI：

  10.1016/j.bmc.2018.08.020

文献信息

• SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability
  作者：Donghong Amy Gao、Zhaoming Xiong、Alexander Heim-Riether、Laura Amodeo、E. Michael August、Xianhua Cao、Leonard Ciccarelli、Brandon K. Collins、Kyle Harrington、Kathleen Haverty、Melissa Hill-Drzewi、Xiang Li、Shuang Liang、Steluta Mariana Margarit、Neil Moss、Nelamangala Nagaraja、John Proudfoot、Rene Roman、Sabine Schlyer、Lana Smith Keenan、Steven Taylor、Bernd Wellenzohn、Dieter Wiedenmayer、Jun Li、Neil A. Farrow

  DOI：10.1016/j.bmcl.2010.07.036

  日期：2010.9

  SAR studies to improve the selectivity and metabolic stability of a class of recently discovered MMP-13 inhibitors are reported. Improved selectivity was achieved by modifying interactions with the S1' pocket. Metabolic stability was improved through reduction of inhibitor lipophilicity. This translated into lower in vivo clearance for the preferred compound. (C) 2010 Elsevier Ltd. All rights reserved.